Subclonal patterns in follow-up of acute myeloid leukemia combining whole exome sequencing and ultrasensitive IBSAFE digital droplet analysis

References

• Grimwade D, Freeman SD. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”? Blood. 2014;124(23):3345–3355.
   PubMed Web of Science ®Google Scholar
• Ivey A, Hills RK, Simpson MA, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374(5):422–433.
   PubMed Web of Science ®Google Scholar
• Kayser S, Walter RB, Stock W, et al. Minimal residual disease in acute myeloid leukemia–current status and future perspectives. Curr Hematol Malig Rep. 2015;10(2):132–144.
   PubMed Web of Science ®Google Scholar
• Ommen HB. Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategies. Ther Adv Hematol. 2016;7(1):3–16. Feb
   PubMed Web of Science ®Google Scholar
• Sung PJ, Luger SM. Minimal residual disease in acute myeloid leukemia. Curr Treat Options Oncol. 2017;18(1):1.
   PubMed Web of Science ®Google Scholar
• Jaso JM, Wang SA, Jorgensen JL, et al. Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future. Bone Marrow Transplant. 2014;49(9):1129–1138.
   PubMed Web of Science ®Google Scholar
• Pettersson L, Leveen P, Axler O, et al. Improved minimal residual disease detection by targeted quantitative polymerase chain reaction in Nucleophosmin 1 type a mutated acute myeloid leukemia. Genes Chromosomes Cancer. 2016;55(10):750–766. Oct
   PubMed Web of Science ®Google Scholar
• Leroy H, de Botton S, Grardel-Duflos N, et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia. 2005;19(3):367–372. Mar
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 2005;352(3):254–266.
   PubMed Web of Science ®Google Scholar
• Bullinger L, Dohner K, Dohner H. Genomics of acute myeloid leukemia diagnosis and pathways. JCO. 2017;35(9):934–946.
   PubMed Web of Science ®Google Scholar
• Ley TJ, Cancer Genome Atlas Research Network, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368(22):2059–2074.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29–41.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–2221.
   PubMed Web of Science ®Google Scholar
• Roloff GW, Lai C, Hourigan CS, et al. Technical advances in the measurement of residual disease in acute myeloid leukemia. J Clin Med. 2017;6(9):pii: E87.
   PubMed Web of Science ®Google Scholar
• Cruz NM, Mencia-Trinchant N, Hassane DC, et al. Minimal residual disease in acute myelogenous leukemia. Int J Lab Hem. 2017;39(Suppl 1):53–60.
   PubMedGoogle Scholar
• Mencia-Trinchant N, Hu Y, Alas MA, et al. Minimal residual disease monitoring of acute myeloid leukemia by massively multiplex digital PCR in patients with NPM1 mutations. J Mol Diagn. 2017;19(4):537–548.
   PubMed Web of Science ®Google Scholar
• Wertheim GBW, Bagg A. NPM1 for MRD? Droplet like it’s hot! J Mol Diagn. 2017;19(4):498–501.
   PubMed Web of Science ®Google Scholar
• Arildsen NS, Martin de la Fuente L, Masback A, et al. Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method. Sci Rep. 2019;9(1):15506.
   PubMedGoogle Scholar
• Fornvik D, Aaltonen KE, Chen Y, et al. Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment. Breast Cancer Res Treat. 2019;177(2):447–455.
   PubMed Web of Science ®Google Scholar
• Isaksson S, George AM, Jonsson M, et al. Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence. Acta Oncologica. 2019;58(8):1079–1086.
   PubMed Web of Science ®Google Scholar
• Lazarevic V, Orsmark-Pietras C, Lilljebjorn H, et al. Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow. Blood. 2018;131(5):577–581.
   PubMed Web of Science ®Google Scholar
• Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;327(8476):307–310.
   Web of Science ®Google Scholar
• Ehinger M, Pettersson L. Measurable residual disease testing for personalized treatment of acute myeloid leukemia. APMIS. 2019;127(5):337–351.
   PubMed Web of Science ®Google Scholar
• Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275–1291.
   PubMed Web of Science ®Google Scholar
• Parkin B, Londono-Joshi A, Kang Q, et al. Ultrasensitive mutation detection identifies rare residual cells causing acute myelogenous leukemia relapse. J Clin Investig. 2017;127(9):3484–3495.
   PubMed Web of Science ®Google Scholar
• Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189–1199.
   PubMed Web of Science ®Google Scholar
• Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9–16.
   PubMed Web of Science ®Google Scholar
• Zink F, Stacey SN, Norddahl GL, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017;130(6):742–752.
   PubMed Web of Science ®Google Scholar
• Corces-Zimmerman MR, Hong WJ, Weissman IL, et al. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. PNAS. 2014;111(7):2548–2553.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488–2498.
   PubMed Web of Science ®Google Scholar
• Shlush LI, Mitchell A, Heisler L, et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017;547(7661):104–108.
   PubMed Web of Science ®Google Scholar
• Shlush LI, Zandi S, Mitchell A, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506(7488):328–333.
   PubMed Web of Science ®Google Scholar
• Sykes SM, Kokkaliaris KD, Milsom MD, et al. Clonal evolution of preleukemic hematopoietic stem cells in acute myeloid leukemia. Exp Hematol. 2015;43(12):989–992.
   PubMed Web of Science ®Google Scholar
• Abelson S, Collord G, Ng SWK, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559(7714):400–404.
   PubMed Web of Science ®Google Scholar
• Rothenberg-Thurley M, Amler S, Goerlich D, et al. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Leukemia. 2018;32(7):1598–1608.
   PubMed Web of Science ®Google Scholar
• Kronke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol. 2011;29(19):2709–2716.
   PubMed Web of Science ®Google Scholar
• Hollein A, Meggendorfer M, Dicker F, et al. NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse. Blood Adv. 2018;2(22):3118–3125.
   PubMed Web of Science ®Google Scholar
• Bacher U, Porret N, Joncourt R, et al. Pitfalls in the molecular follow up of NPM1 mutant acute myeloid leukemia. Haematologica. 2018;103(10):e486–e8.
   PubMed Web of Science ®Google Scholar